Filing Flows › agilon health (AGL) › Stock forecast & fair value
agilon health (AGL) stock forecast and fair value
agilon health (AGL) trades at $109.81. 12 analysts' median price target is $115.00 (+5%), from $85.00 to $146.00. Across 12 valuation methods the middle fair value is $383.83 (+250%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $403.37 | $654.64 | $981.44 | +496% |
| EV/Sales vs peers, weighted | $449.63 | $635.59 | $790.10 | +479% |
| EV/Sales vs peers, growth & margin adjusted | $343.98 | $546.36 | $870.61 | +398% |
| Residual income | −$2.19 | −$2.22 | −$2.25 | -102% |
| Analysts' price targets | $85.00 | $117.75 | $146.00 | +7% |
| Tangible book (asset value) | $7.72 | $9.65 | $9.65 | -91% |
| Survival-weighted value | $373.97 | $606.58 | $909.09 | +452% |
| Stage-weighted value (decline / turnaround) | $237.27 | $383.83 | $573.43 | +250% |
| Combined forecast (3 months) | $89.91 | $114.18 | $141.47 | +4% |
| Schwartz–Moon simulation (cash can run out) | $0.00 | $125.03 | $326.36 | +14% |
agilon health's latest quarter
agilon health, Q3 2026: revenue $1.5B (+6% year over year), operating margin 1.6%, net earnings $34.9M, operating cash flow $49.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AGL stock?
The median of 12 analysts' 12-month targets is $115.00, +5% from $109.81; the range is $85.00 to $146.00. The average rating is buy.
What is agilon health's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$2.22 and $654.64, with a middle value of $383.83 against a price of $109.81. Each method's assumptions are on the page.
Does agilon health usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is AGL stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.